title: Treatment of Retinoblastoma in 2015: Agreement and Disagreement.
abstract: The management of intraocular retinoblastoma is rapidly changing, and even recent reviews on the subject are behind existing practices. The 4 authors of this report collectively represent their management strategies with an emphasis on areas of agreement and disagreement. Ophthalmic artery chemosurgery and intravitreous chemotherapy have completely replaced external beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90% without evidence of compromising patient survival.
authors.affiliation: Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York2Department of Ophthalmology, Weill-Cornell Medical Center, New York, New York.
authors.forename: David H
authors.initials: DH
authors.lastname: Abramson
authors.affiliation: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
authors.affiliation: Jules-Gonin Eye Hospital, Faculté de Biologie et Médecine de Lausanne, Lausanne, Switzerland.
authors.forename: Francis L
authors.initials: FL
authors.lastname: Munier
authors.affiliation: Research Institute, Hospital J.P. Garrahan, Buenos Aires, Argentina.
authors.forename: Guillermo L
authors.initials: GL
authors.lastname: Chantada
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001918:Brachytherapy; D017679:Cryotherapy; D015353:Eye Enucleation; D006801:Humans; D007261:Infusions, Intra-Arterial; D058449:Intravitreal Injections; D017075:Laser Coagulation; D009880:Ophthalmic Artery; D019572:Retinal Neoplasms / Q000473:pathology / Q000628:therapy*; D012175:Retinoblastoma / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents